GlassScriptPhysician profile
Kari Suzanne Light
NPI 1134465826
$3,566.75
in general payments reported to CMS, 2019-2025
19 companies · $766 in 2025
The $766 reported for 2025 was more than what 75% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $841 · 2022: $57.39 · 2023: $719 · 2024: $1,182 · 2025: $766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,668.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,668.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $830.39 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $816.05 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $350.69 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $316.66 | 2021-2024 | |
| Radius Health, INC. | $214.05 | 2021-2025 | Tymlos |
| Pfizer INC. | $184.41 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $145.93 | 2021-2025 | Vaxelis, Vaxneuvance, Proquad |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.81 | 2021-2025 | Jardiance, Tradjenta |
| Amgen INC. | $126.18 | 2021-2025 | Otezla, Repatha, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $123.66 | 2023-2024 | |
| Abbott Laboratories | $70.71 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $68.22 | 2022-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Kowa Pharmaceuticals America, INC. | $49.16 | 2021 | |
| Organon LLC | $38.14 | 2021-2022 | |
| Exact Sciences Corporation | $28.26 | 2023 | Cologuard Collection Kit |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $24.87 | 2024 | Spravato |
| Dexcom, INC. | $16.88 | 2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $16.76 | 2024 | Gvoke Hypopen |
| Alexion Pharmaceuticals, INC. | $13.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kari Light listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.